ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0108 • ACR Convergence 2023

    Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database

    Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
  • Abstract Number: 1605 • ACR Convergence 2023

    Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cecile Yelnik1, Shruti Chaturvedi2, Julien Labreuche1, Xiang-Zuo Pan3, H Michael Belmont4, Kello Nina5, Paul R. Fortin6, D. Ware Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky10, Jane Salmon11, Maria Laura Bertolaccini12, Hannah Cohen13, Michelle Petri14, Doruk Erkan11 and On Behalf Of APS ACTION15, 1University of Lille, Lille, France, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3John Hopkins University, Baltimore, MD, 4NYU School of Medicine, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 7University of Utah, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Johns Hopkins University, Baltimore, MD, 11Hospital for Special Surgery, New York, NY, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 15on behalf of APS ACTION, New York, NY

    Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…
  • Abstract Number: 0109 • ACR Convergence 2023

    Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome

    Bruna Mazetto, NaveenKumar Somanathapura, Claire Hoy, Christine Rysenga, Srilakshmi Yalavarthi, Cyrus Sarosh, Caroline Ranger, Katarina Kmetova, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Inappropriately amplified inflammatory responses are hallmarks of many diseases, with extracellular ATP often playing a central role in the orchestration of inflammation. Regulated cellular…
  • Abstract Number: 1606 • ACR Convergence 2023

    Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation

    NaveenKumar K. Somanathapura, Claire Hoy, Srilakshmi Yalavarthi, Cyrus Sarosh, Bruna De Moraes Mazetto Fonseca, Caroline Ranger, Christine Rysenga, Ajay Tambralli, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: In first responding cells such as neutrophils and platelets, extracellular ATP released from activated or dying cells engages cell-surface receptors to launch proinflammatory and…
  • Abstract Number: 0110 • ACR Convergence 2023

    Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

    Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…
  • Abstract Number: 1607 • ACR Convergence 2023

    Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus

    Eduardo Gomez-Banuelos1, Alessandra Ida Celia2, Maria Isabel Trejo Zambrano3, Merlin Paz3, Erika Darrah3, Daniel Goldman4, Michelle Petri4 and Felipe Andrade3, 1The Johns Hopkins University, Baltimore, MD, 2John Hopkins University of Medicine, Rome, Italy, 3Johns Hopkins University, Baltimore, MD, 4Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
  • Abstract Number: 0111 • ACR Convergence 2023

    Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome

    Wenying Liang1, Allison Billi1, Srilakshmi Yalavarthi1, Christine Rysenga1, Claire Hoy1, Cyrus Sarosh1, Yu Zuo1, Eliza Pei-Suen Tsou1, Jason Knight1 and Hui Shi2, 1University of Michigan, Ann Arbor, MI, 2Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    Background/Purpose: Some patients with antiphospholipid syndrome (APS) are afflicted by an insidious small-vessel vasculopathy that results in the accrual of organ damage over time. While…
  • Abstract Number: 1608 • ACR Convergence 2023

    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Ayesha Butt1, Rolando Garcia Milian1, George Goshua1, Sean Gu1, Eugenia Chock2, Valentina Restrepo1, John Hwa1, Hyung Chun1, H Michael Belmont3, Kello Nina4, D. Ware Branch5, Michelle Petri6, Jason Knight7, Rohan Willis8, Maria Laura Bertolaccini9, Doruk Erkan10, Alfred lee1, Anish Sharda1 and Alexander Pine11, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Greenwich, CT, 3NYU School of Medicine, New York, NY, 4Northwell Health, Brooklyn, NY, 5University of Utah, Salt Lake City, UT, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7University of Michigan, Ann Arbor, MI, 8University of Texas Medical Branch, Galveston, TX, 9King's College London, London, United Kingdom, 10Hospital for Special Surgery, New York, NY, 11VA Connecticut/Yale School of Medicine, West Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
  • Abstract Number: 0674 • ACR Convergence 2022

    Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies

    Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA

    Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…
  • Abstract Number: 0690 • ACR Convergence 2022

    The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis

    Ajay Tambralli1, Alyssa Harbaugh1, Christine Rysenga1, Kaitlyn Sabb1, Srilakshmi Yalavarthi1, Claire Hoy1, Yu (Ray) Zuo1 and Jason S Knight2, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
  • Abstract Number: 0675 • ACR Convergence 2022

    Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort

    Jose A Meade-Aguilar1, Gabriel Figueroa Parra1, Hannah Langenfeld2, Rodrigo Cartin-Ceba1, Ulrich Specks1, Cynthia Crowson3 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN

    Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…
  • Abstract Number: 0691 • ACR Convergence 2022

    Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls

    Hannah Britt1, Hannah Bradford1, Valentina Spiteri1, Anisur Rahman2, Ian Giles1, Mihaela Delcea3, Paul Dalby1, Kostas Thalassinos1 and Thomas McDonnell1, 1University College London, London, United Kingdom, 2Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 3University of Greifswald, Greifswald, Germany

    Background/Purpose: Beta-2-Glycoprotein I (B2GPI) is a serum protein of approximately 50kDa and is the main autoantigen of Antiphospholipid syndrome (APS). Antibodies to B2GPI (aB2GPI) are…
  • Abstract Number: 0676 • ACR Convergence 2022

    Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

    Jose A Meade-Aguilar1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Hannah Langenfeld2, Prerna Dogra1, Irina Bancos3, Hassan Murad3, Cynthia Crowson4 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Eyota, MN

    Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
  • Abstract Number: 0692 • ACR Convergence 2022

    The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis

    Naveen Kumar S K1, Claire Hoy1, Christine Rysenga1, Srilakshmi Yalavarthi1, Cyrus Sarosh2, Sherwin Navaz1, Jacqueline Madison1, Jason S Knight3 and Yu (Ray) Zuo1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI, 3University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…
  • Abstract Number: 0677 • ACR Convergence 2022

    Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual

    Gustavo Balbi1, Flavio Victor Signorelli2, Ana Paula Gandara3, Indira Azam3, Dilson Marreiros3, Luciano Drager3 and Danieli Castro Oliveira de Andrade4, 1Universidade de São Paulo, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 3University of São Paulo, São Paulo, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology